Fascination About Tyrosinase-IN-12
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine to evaluate a number of intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Primary trial objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polym